Peter Lio, MD, FAAD
Clinical Assistant Professor, Dermatology and Pediatrics
Northwestern University School of Medicine
Founding Director, Chicago Integrative Eczema Center
Elaine Siegfried, MD
Director of Pediatric Dermatology
SSM Cardinal Glennon Children’s Medical Center
Professor, Pediatric and Dermatology
Saint Louis University School of Medicine
St. Louis, MO
This enduring activity will explore the management of moderate-to-severe atopic dermatitis (AD) in pediatric and adolescent patients. Innovative whiteboard animations will review the mechanism of action of systemic therapies for AD and the impact of COVID-19 on treatment selection. A review of clinical trial data, guideline recommendations, and patient-specific factors that impact management decisions will help clinicians develop personalized treatment plans and improve patient outcomes.
This activity is intended for pediatricians, dermatologists, pediatric dermatologists, primary care physicians, and other healthcare professionals involved in the management of pediatric and adolescent patients with atopic dermatitis.
After participating in this educational initiative, clinicians should be better able to:
- Assess the benefits and risks of using systemic immunosuppressants and immunomodulators during the COVID-19 pandemic
- Evaluate clinical trial data on the efficacy and safety of systemic therapies for the management of moderate-to-severe atopic dermatitis in children and adolescents
- Develop personalized treatment plans that address disease severity, patient-specific factors, and quality of life in children and adolescents with atopic dermatitis
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
This CME activity was planned and produced in accordance with the ACCME Essentials.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 1.50 AMA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSING CREDIT INFORMATION
Purpose: This program would be beneficial for nurses involved in the care of patients with atopic dermatitis.
CNE Credits: 1.50 ANCC Contact Hours.
CNE ACCREDITATION STATEMENT
Ultimate Medical Academy/CCM is accredited as a provider of nursing continuing professional education development by the American Nurses Credentialing Center’s Commission on Accreditation.
Awarded 1.50 contact hours of continuing nursing education of RNs and APNs.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education ACCME Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF FINANCIAL RELATIONSHIPS
Dr. Lio reports the following disclosures:
|Speaker Bureau||Regeneron/Sanofi Genzyme, Pfizer, Eli Lilly, LEO, Galderma, and L’Oreal|
|Consulting/Advisory Boards||AbbVie, Altus Labs, AOBiome, Arbonne, Amyris, Bodewell, Burt’s Bees, Dermavant, Eli Lilly, Exeltis, Galderma, IntraDerm, Johnson & Johnson, Kimberly-Clark, L’Oreal, Level Ex, LEO Pharmaceuticals, Menlo Therapeutics, Micreos, My-Or Diagnostics, Pfizer, Pierre-Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, UCB, Unilever, Verrica, YobeeCare|
|Research Grants/Funding||AbbVie, AOBiome, National Eczema Association, Regeneron/Sanofi Genzyme|
|Pending Patent with Royalties||Theraplex product|
|Board member and Scientific Advisory Committee Member||National Eczema Association|
|Stock Options||Altus Labs/Franklin, Micreos, YobeeCare|
Dr. Siegfried reports the following disclosures:
|Speaker Bureau||Regeneron, Sanofi Genzyme, Verrica|
|Consulting Fee||AbbVie, ASLAN Pharmaceuticals, Boehringer Ingelheim, Incyte, LEO, Novan, Novartis, Pfizer, Pierre Fabre, Regeneron, Sanofi Genzyme, UCB, Verrica|
|Contracted Research||AI Therapeutics|
|SSM/SLU – Clinical Trials||Janssen, Lilly, Pierre Fabre, Regeneron, Verrica|
|Scientific Advisory Committee Member||National Eczema Association|
|Data Safety Monitoring Board||Leo, Novan, Pfizer, UCB|
|Grant||Pfizer (2020-2022 Peds Derm Fellow)|
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
Douglas Cox, MSN, MHA, RN
Ultimate Medical Academy/CCM – Lead Nurse Planner
The reviewer of this activity has nothing to disclose.
Staff Planners and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
- Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
- Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
- Diana Tommasi, PharmD, Medical Director for Med Learning Group has nothing to disclose.
- Nicole Longo, DO, FACOI, Director of Medical and Scientific Services of Med Learning Group, has nothing to disclose.
- Douglas Cox, MSN, MHA, RN, UMA/CCM – LNP, has nothing to disclose.
- Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
- Daniel Dasilva, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.
- Felecia Beachum, Program Manager for Med Learning Group, has nothing to disclose.
- Naomi De Brito, Program Coordinator for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During this lecture, the faculty may mention the use of medications for both FDA-approved and nonapproved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CNE credit participants must:
- Read the CME/CNE information and faculty disclosures.
- Participate in the enduring activity.
- Complete the online post-test and evaluation.
You will receive your certificate as a downloadable file.
Med Learning Group makes every effort to develop CME activities that are science-based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at [email protected]
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at https://medlearninggroup.com/privacy‐policy/.
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
Copyright © 2022 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.